Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Lupus Nephritis (LN) Clinical Trials

7 recruiting trials for Lupus Nephritis (LN). Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
7
Total Trials
7
Recruiting Now
0
Phase 3 Trials
5
Sponsors

Recruiting Trials

RECRUITINGPhase 1NCT07236762

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and...

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.Enrolling: 181 location
RECRUITINGPhase 2NCT07340463

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis...

1. Study Design This is a single-center, prospective, randomized, controlled, exploratory clinical trial. The study is designed to evaluate and compare the efficacy and safety of...

Sponsor: Nanjing University School of MedicineEnrolling: 501 location
RECRUITINGNCT06927219

Research Accelerated by You Lupus Registry

Summary The Lupus Foundation of America (LFA) Research Accelerated by You (RAY) Registry is a fully remote, longitudinal registry designed to collect data from adults and children...

Sponsor: Lupus Foundation of AmericaEnrolling: 100001 location
RECRUITINGPhase 1NCT07104721

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and...

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.Enrolling: 181 location
RECRUITINGPhase 1NCT07123519

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and...

Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.Enrolling: 181 location
RECRUITINGPhase 2NCT07363460

Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

A double-blind,placebo controlled,randomized Phase 2 study to evaluate the safety and tolerability of once-daily, oral administration of 200 or 300 mg HSK39297 tablets versus...

Sponsor: Haisco Pharmaceutical Group Co., Ltd.Enrolling: 1051 location
RECRUITINGNCT06902844

Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

This is a single-center, open-label, exploratory clinical study to evaluate the efficacy and safety of Equecabtagene Autoleucel Injection (Eque-cel) in patients with Relapsed...

Sponsor: Tongji HospitalEnrolling: 61 location